|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Belongs to our Healthcare sector and High P/E group with a P/E of 111,68.
The stocks were selected based on their earnings, growth potential and risk of financial distress. These factors were determined by the company’s P/E-ratios, growth estimates and the strength of their financial positions.
202 of stock are bought. The stock is ranked 23 based on the best performing YTD returns of the s&p-500 index from start of the year until 3.11.2020 which is in line with our momentum strategy. 202 stocks are bought so that the target weight of 2.5% (+-1%) would be achieved in the portfolio.
Long position. Part of our passive small cap healthcare investment strategy. The initial position (~10% of our portfolio @ leverage of 1) is based on our selection of the smallest cap stocks in the S&P 500 Healthcare index in the same proportion as the stock's share of the whole index. The limit of a stock's weight in our portfolio is 15% and rebalancing will be accordingly.
The fund follows the return seasonality strategy by investing into stocks with exceptionally high or low returns during the same-calendar-months. This stock has had top 10 highest February- returns within the S&P 500 -index during the last decade. The portfolio will be equally weighted between 10 long and 10 short positions on different stocks.
Initial short positions of the fund will be based on the worst-performing stocks of S&P500 in 2019. Abiomed among the worst-performing stocks and will have an equally weighted share within the fund.